<scp>PDE4</scp> Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

Phosphodiesterase 4 (PDE4) enzymes play a central role in modulating cyclic adenosine monophosphate (cAMP) signaling and regulating diverse cellular responses. Inhibitors of PDE4 have emerged as safe and effective anti-inflammatory therapies across multiple dermatologic diseases, and growing evidence suggests that PDE4 inhibition exerts broader effects on skin physiology. This review synthesizes mechanistic, preclinical, and clinical evidence describing the multifaceted roles of PDE4 inhibition in the skin. A comprehensive literature review was conducted using PubMed/MEDLINE, Embase, and ClinicalTrials.gov through 2025. Search terms included "PDE4," "phosphodiesterase 4," and both approved and investigational therapies, including "apremilast," "crisaborole," "roflumilast," and "orismilast." Relevant preclinical studies, clinical trials, and mechanistic investigations were included. PDE4 inhibition prevents cAMP degradation and activates protein kinase A (PKA) signaling, leading to broad biologic effects in the skin. Beyond well-established anti-inflammatory actions, PDE4 inhibitors appear to influence melanocyte signaling and pigmentation, enhance epidermal barrier protein expression, modulate sensory neuron activity, and promote wound healing by reducing fibrosis. These effects have been demonstrated mechanistically and across multiple dermatologic conditions and may help explain clinical observations. Heterogeneity in study design, limited long-term data, and variability in PDE4 isoform selectivity across studies may limit generalizability. Further mechanistic and comparative clinical studies are needed to better define therapeutic impact. PDE4 inhibitors represent a unique therapeutic class with pleiotropic effects across multiple disease states, including regulation of pigmentation, barrier integrity, neural signaling, and tissue repair. Their ability to integrate immunologic and non-immunologic pathways highlights their role in maintaining cutaneous homeostasis and expanding therapeutic potential in dermatology.

Authors

Institutions

Publication Details

Journal
International Journal of Dermatology
Published
2026-05-17
DOI
https://doi.org/10.1111/ijd.70456
Primary Topic
Phosphodiesterase function and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

Nicole E. Chin, Keana Khodadad, Raj Chovatiya
International Journal of Dermatology
Phosphodiesterase function and regulation
article

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

Nicole E. Chin, Keana Khodadad, Raj Chovatiya
article en

Abstract

Phosphodiesterase 4 (PDE4) enzymes play a central role in modulating cyclic adenosine monophosphate (cAMP) signaling and regulating diverse cellular responses. Inhibitors of PDE4 have emerged as safe and effective anti-inflammatory therapies across multiple dermatologic diseases, and growing evidence suggests that PDE4 inhibition exerts broader effects on skin physiology. This review synthesizes mechanistic, preclinical, and clinical evidence describing the multifaceted roles of PDE4 inhibition in the skin. A comprehensive literature review was conducted using PubMed/MEDLINE, Embase, and ClinicalTrials.gov through 2025. Search terms included "PDE4," "phosphodiesterase 4," and both approved and investigational therapies, including "apremilast," "crisaborole," "roflumilast," and "orismilast." Relevant preclinical studies, clinical trials, and mechanistic investigations were included. PDE4 inhibition prevents cAMP degradation and activates protein kinase A (PKA) signaling, leading to broad biologic effects in the skin. Beyond well-established anti-inflammatory actions, PDE4 inhibitors appear to influence melanocyte signaling and pigmentation, enhance epidermal barrier protein expression, modulate sensory neuron activity, and promote wound healing by reducing fibrosis. These effects have been demonstrated mechanistically and across multiple dermatologic conditions and may help explain clinical observations. Heterogeneity in study design, limited long-term data, and variability in PDE4 isoform selectivity across studies may limit generalizability. Further mechanistic and comparative clinical studies are needed to better define therapeutic impact. PDE4 inhibitors represent a unique therapeutic class with pleiotropic effects across multiple disease states, including regulation of pigmentation, barrier integrity, neural signaling, and tissue repair. Their ability to integrate immunologic and non-immunologic pathways highlights their role in maintaining cutaneous homeostasis and expanding therapeutic potential in dermatology.

International Journal of Dermatology
Rosalind Franklin University of Medicine and Science (US), Loyola University Chicago (US)
Good health and well-being
Openalex Percentile: Top 9%
Phosphodiesterase function and regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.